3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Interventions
pembrolizumab
1024
Carboplatin
966
Paclitaxel
933
Gemcitabine
794
Cisplatin
753
Docetaxel
684
Bevacizumab
609
Pemetrexed
504
Nivolumab
487
Cyclophosphamide
474
Capecitabine
461
Fluorouracil
418
Dexamethasone
403
Rituximab
373
Oxaliplatin
348
Injections
347
atezolizumab
298
Trastuzumab
298
Leucovorin
288
Cetuximab
282
Irinotecan
268
130-nm albumin-bound paclitaxel
254
Prednisone
246
Doxorubicin
241
Ipilimumab
226
fludarabine
220
Lenalidomide
220
Fulvestrant
217
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
SR 48692
×
Clear all
NCT00290953
2008-12-23
SESAME
Sanofi
Phase 2/3
Completed
432 enrolled